Patient baseline characteristics
| Total (n = 84) . | |
|---|---|
| Age | 62 (43-85) |
| ≥65 y | 31 (37%) |
| ≥75 y | 8 (10%) |
| Sex | |
| Male | 44 (52%) |
| Female | 40 (48%) |
| Ethnic origin | |
| White | 68 (81%) |
| Black or African American | 11 (13%) |
| Asian | 4 (5%) |
| East Indian | 1 (1%) |
| ECOG performance status | |
| 0 | 15 (18%) |
| 1 | 68 (81%) |
| 2 | 1 (1%) |
| Prior therapies | 6 (1-16) |
| 1 | 1 (1%) |
| 2-3 | 12 (14%) |
| 4-6 | 32 (38%) |
| 7-9 | 24 (29%) |
| ≥10 | 15 (18%) |
| Types of prior therapies | |
| Proteasome inhibitor | 83 (99%) |
| IMiD | 82 (98%) |
| Alkylating agent | 83 (99%) |
| CD38 antibody | 5 (6%) |
| Topoisomerase II inhibitor | 21 (25%) |
| Steroid | 84 (100%) |
| Stem cell transplant | 45 (54%) |
| Total (n = 84) . | |
|---|---|
| Age | 62 (43-85) |
| ≥65 y | 31 (37%) |
| ≥75 y | 8 (10%) |
| Sex | |
| Male | 44 (52%) |
| Female | 40 (48%) |
| Ethnic origin | |
| White | 68 (81%) |
| Black or African American | 11 (13%) |
| Asian | 4 (5%) |
| East Indian | 1 (1%) |
| ECOG performance status | |
| 0 | 15 (18%) |
| 1 | 68 (81%) |
| 2 | 1 (1%) |
| Prior therapies | 6 (1-16) |
| 1 | 1 (1%) |
| 2-3 | 12 (14%) |
| 4-6 | 32 (38%) |
| 7-9 | 24 (29%) |
| ≥10 | 15 (18%) |
| Types of prior therapies | |
| Proteasome inhibitor | 83 (99%) |
| IMiD | 82 (98%) |
| Alkylating agent | 83 (99%) |
| CD38 antibody | 5 (6%) |
| Topoisomerase II inhibitor | 21 (25%) |
| Steroid | 84 (100%) |
| Stem cell transplant | 45 (54%) |
Data are median (range), n (%) or n. Data include 3 patients with WM.